Selective inhibition of MALT1 protease by phenothiazine derivatives

US9504692B2 · kind B2 · utility

Assignee

• Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · DE

Inventors

• Daniel Krappmann · Hersbruck, DE
• Daniel Nagel · Quincy, US
• Dolores Schendel · Munich, DE
• Stefani Spranger · Chicago, US

Key dates

• Filing date: Aug 1, 2012
• Grant date: Nov 29, 2016
• Expiry date: Aug 1, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D279/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I)wherein X is N or C; Y is S, O, SO2, SO, NH, CO, CH2, CH═CH, or CH2—CH2; ( )z is a C1-C5 linear or branched alkyl chain; A is NR3R4, or OR5, or HET; R1 and R2 in each occurrence are independently selected from —H, —CH3, —OH, —OCH3, —SCH3, —F, —Cl, —CF3, —NH2, and —COOH; R3, R4, and R5 are H, or C1-C5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C1-C5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of MALT1-dependent immune diseases.